Provided by Tiger Trade Technology Pte. Ltd.

YZYBIO-B

2.205
-0.985-30.88%
Volume:600
Turnover:1K
Market Cap:427.77M
PE:-4.31
High:2.200
Open:2.200
Low:2.200
Close:3.190
52wk High:8.400
52wk Low:2.200
Shares:194.00M
HK Float Shares:179.48M
Volume Ratio:- -
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.512
ROE:-704.81%
ROA:-7.87%
PB:-6.24
PE(LYR):-4.31
PS:6.27

Loading ...

YZYBIO-B Requests One-Month Extension to Dispatch Circular on Connected Share Issue and Whitewash Waiver

Bulletin Express
·
Sep 30

YZYBIO-B (02496): Mak Sin Kei Appointed as Authorized Representative for Service of Process

Stock News
·
Sep 30

YZYBIO-B Interim 2026: Net Loss Shrinks to RMB6.26 Million on Milestone Licensing Income and Sharp R&D Cut

Bulletin Express
·
Sep 16

YZYBIO-B: Hongfeng Zhou Acquires Shares, Long Position Rises to 247.68%

HK Disclosure
·
Sep 15

YZYBIO-B: Qian Yuan Acquires Shares, Long Position Rises to 247.68%

HK Disclosure
·
Sep 15

Trading in YZYBIO-B Resumes on September 10 Morning

Stock News
·
Sep 10

YZYBIO-B Plans RMB83 Million Connected Share Placement; Founders Seek Whitewash Waiver to Lift Concerted Stake Above 50%

Bulletin Express
·
Sep 09

Wuhan YZY Biopharma Co - to Issue 35.6 Mln Domestic Shares at Rmb2.43 Per Share

THOMSON REUTERS
·
Sep 09

YZYBIO-B Maintains Stable Share Base in August; 0.50 Million Options Lapse Under 2024 Plan

Bulletin Express
·
Sep 03

YZYBIO-B Trading Halt Announced Pending Insider Information Disclosure

Deep News
·
Aug 31

Trading in Wuhan YZY Biopharma H Shares Halted at 9:00 A.m. on Aug 31, 2026

THOMSON REUTERS
·
Aug 31

YZYBIO-B Reports Narrowed Interim Loss of RMB 6.26 Million, Down 89.36% Year-on-Year

Stock News
·
Aug 28

YZYBIO-B Narrows H1 Loss on Lower R&D Spend; M701 NDA Accepted, Pipeline Advances

Bulletin Express
·
Aug 28

Wuhan YZY Biopharma H1 FY26 Net Loss Narrows to RMB 6.26 Million; Revenue Falls 10.87% to RMB 33.14 Million

Reuters
·
Aug 28

YZYBIO-B schedules 28 Aug 2026 board session to approve 1H 2026 interim results

Bulletin Express
·
Aug 18

Wuhan YZY Biopharma Schedules Board Meeting to Review Interim Results

Reuters
·
Aug 18

YZY Biopharma Reports No Change in Share Capital for July 2026; 1.25 Million Options Outstanding

Bulletin Express
·
Aug 05

YZYBIO-B (02496) to Present Clinical Data for M701 at 2026 ASCO Annual Meeting

Stock News
·
May 22

Wuhan YZY Biopharma says Phase III M701 trial prolongs puncture-free survival in malignant ascites

Reuters
·
May 22

YZYBIO-B Announces Supervisor Transition: Dr. Shi Jian Steps Down, Ms. Fang Lijuan Elected as Employee Representative

Bulletin Express
·
May 15